Docetaxel plus prednisolone in crpc Chinese patints
Best insight from top research papers
Docetaxel plus prednisolone has been found to be effective and well-tolerated in Chinese patients with castration-resistant prostate cancer (CRPC) . Studies have shown that this combination therapy can lead to a significant reduction in prostate-specific antigen (PSA) levels, with response rates ranging from 50% to 66.67% . The median number of cycles completed was 10, and the median overall survival was 19 months . Adverse events were generally manageable, with hematological toxicities being the most common, including neutropenia and febrile neutropenia . Other adverse reactions such as bone pain, fatigue, and alopecia were also observed . However, the addition of prednisolone was associated with an increased risk of anaemia and neuropathy . Overall, docetaxel plus prednisolone has shown promise as a treatment option for Chinese patients with CRPC, but further research with larger sample sizes is needed to confirm these findings.
Answers from top 4 papers
More filters
| Papers (4) | Insight |
|---|---|
Open access•Journal Article 4 Citations | The paper compares the efficacy of docetaxel plus prednisone and mitoxantrone plus prednisone for treating metastatic hormone-refractory prostate cancer in Chinese patients. It does not specifically mention the use of prednisolone. |
| The paper discusses the feasibility and efficacy of docetaxel plus prednisone for Chinese patients with metastatic castration refractory prostate cancer (mCRPC). It concludes that the docetaxel plus prednisone regimen is safe, tolerable, and effective for Chinese patients with mCRPC. | |
| The paper discusses the use of docetaxel plus prednisone chemotherapy in Chinese elderly men with metastatic castration-resistant prostate cancer (mCRPC). The study shows that this treatment is tolerable and effective in these patients. | |
Open access•Journal Article | The paper discusses the effects of docetaxel in combination with prednisone in Mandarin Chinese patients with castration-resistant prostate cancer (CRPC). It found that the treatment was effective with manageable adverse effects. |
Related Questions
What experimental CRC model in mice?4 answersExperimental colorectal cancer (CRC) models in mice include carcinogen-induced models (CIMs), genetically engineered mouse models (GEMMs), periodontitis-induced models, and xenograft models. CIMs are valuable for studying colitis-related carcinogenesis and chemoprevention, while GEMMs help evaluate the tumor microenvironment and immune responses, aiding in the discovery of novel therapies. Periodontitis-induced models, such as ligature-induced periodontitis, have been shown to promote CRC by reshaping the microbiota and suppressing the immune response. Additionally, xenograft models, like patient-derived xenografts (PDX), are reliable for preclinical drug development due to their retention of pathological and molecular characteristics. These diverse murine models play crucial roles in advancing our understanding and treatment of CRC.
How can flouroquinalones affect crc?5 answersFluoroquinolones can affect the quality characteristics and oxidation stability of cooked and raw beef burger. They can also affect the physicochemical composition, pH, cooking parameters, color, and texture characteristics of the burger. In addition, the addition of quinoa flour, which contains polyphenols, can affect dough stability and optimum mixing time in wheat flour. Quinoa flour can also contribute to postacidification of fermented milk during storage. Furthermore, the addition of quinoa bran to gluten-free bread can improve its volume, pore size, and sensory acceptance. Quinoa flour can also enhance the properties of gluten-free bread, such as physicochemical properties, rheological properties, and microstructure. However, further research is needed to determine the specific effects of fluoroquinolones on CRC, as this information is not provided in the abstracts.
How are corticosteroids used in cancer patients?5 answersCorticosteroids are commonly used in oncology for various indications, including refractory symptoms, anti-cancer effects, supportive measures for cancer-specific treatments, and management of immune-related adverse events induced by immunotherapies. They are often prescribed as first-line treatments in oncological emergencies due to their rapid effect and wide range of actions. While preclinical studies suggest that corticosteroid-induced immunosuppression may dampen the activity of immunotherapies, clinical studies show that corticosteroid use does not significantly alter patient response to immunotherapies. Corticosteroids are also commonly used to manage cancer-related symptoms and improve quality of life in advanced cancer patients. Additionally, corticosteroids have been investigated in combination with cancer chemotherapy, with certain glucocorticoid receptor modulators showing potential benefits in treating cancer. Overall, corticosteroids play a crucial role in the management of cancer patients, providing symptom relief, supportive care, and addressing specific treatment-related issues.
What are the side effects of corticosteroids in cancer patients?5 answersCorticosteroids are commonly used in cancer patients and can lead to various side effects. Neurological complications can arise as a result of corticosteroid use, as well as from other supportive care medications used in oncology. These complications can have a significant impact on patient quality of life. Adverse events associated with corticosteroid use include nausea and vomiting, dyspepsia, hyperglycemia, oral candidiasis, and proximal myopathy. Corticosteroids have also been associated with neuropsychiatric toxicity, ranging from insomnia and cognitive impairment to severe mental disorders such as mania, psychosis, and severe depression. The optimal treatment and prevention of steroid-induced mental disorders in cancer patients is still unclear due to a lack of evidence. It is important for clinicians to be aware of these potential side effects and to actively manage and minimize their occurrence.
What is the range of CRP serum concentrations in tumour tissues of colorectal cancer patients?4 answersThe range of CRP serum concentrations in tumour tissues of colorectal cancer patients varies. One study found that CRP levels were significantly higher in patients with inoperable tumours compared to those who had undergone complete surgery. Another study reported that CRP concentration evaluation may have an advantage as a prognostic biomarker in colorectal cancer patients, as it reflects clinicopathological features of the tumour. Additionally, a study found that an elevated preoperative serum CRP level was associated with a poor prognosis in patients with stage IV colorectal cancer. However, the specific range of CRP serum concentrations in tumour tissues was not mentioned in any of the abstracts provided.
Can Covid vaccine be given while on prednisone?6 answers